Author

Galina Statsenko

Observed names: G Statsenko, G. B. Statsenko, G. Statsenko, G.B. Statsenko, Galina B. Statsenko, Галина Стаценко

Institution: Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Observed institution: Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

ORCID: 0000-0001-7123-8639

Observed ORCID: 0000-0001-7123-8639

OpenAlex ID: A5022023816

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,456

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 742

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

2020 · Thomas Powles, Michiel S van der Heijden, et al. · The Lancet Oncology · 518

PDF

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

2022 · L. Paz-Ares, Y. Chen, et al. · ESMO Open · 383

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

2025 · Jeffrey D. Bradley, Shunichi Sugawara, et al. · Journal of Clinical Oncology · 99

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

2023 · Luis Paz-Ares, Marina Chiara Garassino, et al. · Clinical Cancer Research · 68

PDF

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

2020 · Jonathan W. Goldman, Marina Chiara Garassino, et al. · Lung Cancer · 60

PDF

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

2022 · Yuanbin Chen, Luis Paz-Ares, et al. · JTO Clinical and Research Reports · 55

PDF

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

2019 · L. Paz-Ares, J.W. Goldman, et al. · Annals of Oncology · 54

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

2020 · Luis G. Paz-Ares, Mikhail Dvorkin, et al. · Journal of Clinical Oncology · 48

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

2017 · Ilya Tsimafeyeu, Tatiana Zolotareva, et al. · Clinical Genitourinary Cancer · 34

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

2020 · J.W. Goldman, M.C. Garassino, et al. · Annals of Oncology · 32

PDF

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

2019 · L. Paz-Ares, Y. Chen, et al. · Journal of Thoracic Oncology · 22

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.

2020 · Yuanbin Chen, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 15

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

2021 · L. Paz-Ares, Y. Chen, et al. · Annals of Oncology · 13

PDF

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

2020 · Ilya Tsimafeyeu, Oxana Shatkovskaya, et al. · Cancer Reports · 13

PDF

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

2023 · Ilya Tsimafeyeu, Galina Statsenko, et al. · Investigational New Drugs · 12

PDF

Overall Survival of Patients With ALK-Positive Metastatic Non–Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study

2019 · Ilya Tsimafeyeu, Fedor Moiseenko, et al. · Journal of Global Oncology · 10

Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

2025 · Niels Reinmuth, Jonathan W. Goldman, et al. · Clinical Lung Cancer · 8

PDF

Survival of patients with metastatic bladder cancer in the Russian Federation: results of a multicenter registry study URRU

2021 · I. V. Tsimafeyeu, G. N. Alekseeva, et al. · Cancer Urology · 7

PDF

Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study

2019 · I. V. Tsimafeyeu, I. S. Varlamov, et al. · Malignant tumours · 6

PDF

Approaches to the diagnosis and treatment of patients with stage III—IV non-small cell lung cancer in Russia. Preliminary results of a prospective multicenter non-interventional observational study KARL

2023 · K.K. Lactionov, E.V. Reutova, et al. · P A Herzen Journal of Oncology · 5

141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

2022 · N. Reinmuth, J.W. Goldman, et al. · Annals of Oncology · 5

PDF

The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: An analysis of URRU register.

2021 · Vladislav Petkau, Galina Alekseeva, et al. · Journal of Clinical Oncology · 4

Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5.

2017 · Ilya Tsimafeyeu, Tatiana Zolotareva, et al. · Journal of Clinical Oncology · 4

Works count: 125

Citation count: 7,891

H-index: 15

I10-index: 20